1-4 of 4
Natasja Brooijmans
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts

Leonard Buckbinder, David J. St. Jean, Jr, Trang Tieu, Brendon Ladd, Brendan Hilbert, Weixue Wang, Jacob T. Alltucker, Samantha Manimala, Gregory V. Kryukov, Natasja Brooijmans, Gregory Dowdell, Philip Jonsson, Michael Huff, Angel Guzman-Perez, Erica L. Jackson, Marcus D. Goncalves, Darrin D. Stuart
Journal: Cancer Discovery
Cancer Discov (2023) 13 (11): 2432–2447.
https://doi.org/10.1158/2159-8290.CD-23-0396
Published: 01 November 2023
View article titled, STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts
Open the PDF for STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts in another window
Includes: Supplementary data
Journal Articles

Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science

Darrin D. Stuart, Angel Guzman-Perez, Natasja Brooijmans, Erica L. Jackson, Gregory V. Kryukov, Adam A. Friedman, Axel Hoos
Journal: Cancer Discovery
Cancer Discov (2023) 13 (10): 2131–2149.
https://doi.org/10.1158/2159-8290.CD-23-0280
Published: 05 October 2023
View article titled, Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science
Open the PDF for Precision Oncology Comes of Age: Designing Best-in-Class Small Molecules by Integrating Two Decades of Advances in Chemistry, Target Biology, and Data Science in another window
Journal Articles

Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma

Megan A. Hatlen, Oleg Schmidt-Kittler, Cori Ann Sherwin, Emily Rozsahegyi, Nooreen Rubin, Michael P. Sheets, Joseph L. Kim, Chandrasekhar Miduturu, Neil Bifulco, Natasja Brooijmans, Hongliang Shi, Timothy Guzi, Andy Boral, Christoph Lengauer, Marion Dorsch, Richard D. Kim, Yoon-Koo Kang, Beni B. Wolf, Klaus P. Hoeflich
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2019) 9 (12): 1686–1695.
https://doi.org/10.1158/2159-8290.CD-19-0367
Published: 02 December 2019
View article titled, Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Open the PDF for Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Margit Hagel, Chandra Miduturu, Michael Sheets, Nooreen Rubin, Weifan Weng, Nicolas Stransky, Neil Bifulco, Joseph L. Kim, Brian Hodous, Natasja Brooijmans, Adam Shutes, Christopher Winter, Christoph Lengauer, Nancy E. Kohl, Timothy Guzi
Journal: Cancer Discovery
Series: Author Choice
Cancer Discov (2015) 5 (4): 424–437.
https://doi.org/10.1158/2159-8290.CD-14-1029
Published: 05 April 2015
View article titled, First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
Open the PDF for First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway in another window
Includes: Supplementary data